Public Employees Retirement System of Ohio Cuts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Public Employees Retirement System of Ohio cut its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,862 shares of the life sciences company's stock after selling 5,915 shares during the period. Public Employees Retirement System of Ohio's holdings in Illumina were worth $7,546,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Industrial Alliance Investment Management Inc. purchased a new stake in Illumina during the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV grew its stake in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in Illumina during the 2nd quarter valued at about $61,000. Private Trust Co. NA raised its position in Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after purchasing an additional 212 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. purchased a new stake in Illumina in the 2nd quarter worth approximately $63,000. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of Illumina stock traded down $2.56 on Friday, hitting $143.87. 1,808,511 shares of the company traded hands, compared to its average volume of 2,009,685. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The business has a 50-day simple moving average of $144.22 and a 200 day simple moving average of $128.02. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a market capitalization of $22.82 billion, a P/E ratio of -14.70 and a beta of 1.11.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.08 billion. During the same period in the previous year, the firm posted $0.33 earnings per share. The business's revenue was down 3.5% compared to the same quarter last year. Research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Daiwa America upgraded Illumina to a "strong-buy" rating in a research report on Friday, August 16th. Barclays upped their price target on Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Daiwa Capital Markets raised Illumina from a "neutral" rating to a "buy" rating and raised their price objective for the company from $120.00 to $154.00 in a research report on Friday, August 16th. Finally, Citigroup downgraded shares of Illumina from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $190.00 to $165.00 in a research report on Wednesday. Nine investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $165.86.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.